Pankti Reid, MD, MPH, discusses remaining challenges regarding the management of immune-related adverse effects.
Pankti Reid, MD, MPH, rheumatologist, assistant professor of medicine, University of Chicago Medicine, discusses remaining challenges regarding the management of immune-related adverse effects (irAEs).
Although the advent of multidisciplinary toxicity teams has facilitated efficient evaluation and management of multi-organ irAEs, challenges remain, Reid says. Moreover, optimization of diagnostic tools and identification of efficacious therapies beyond steroids, is needed.
Systemic steroids, which are currently the standard of care for managing irAEs, are associated with significant toxicities of their own, explains Reid. Additionally, managing irAEs often calls for high-dose steroids given over a long period of time.
As such, developing steroid-sparing regimens is necessary to reduce the potential impact of treatment for irAEs, concludes Reid.
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer
2 Commerce Drive
Cranbury, NJ 08512